Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 18 11 2017
accepted: 20 04 2018
revised: 28 03 2018
pubmed: 27 6 2018
medline: 12 2 2019
entrez: 27 6 2018
Statut: ppublish

Résumé

To compare MR imaging with or without DWI and clinical response evaluation (CRE) in the local control evaluation of cervical carcinoma after radiotherapy. In a multicentre university setting, we prospectively included 107 patients with primary cervical cancer treated with radiotherapy. Sensitivity and specificity for CRE and MR imaging (with pre-therapy MR imaging as reference) (2 readers) were evaluated using cautious and strict criteria for identifying residual tumour. Nested logistic regression models were constructed for CRE, subsequently adding MR imaging with and without DWI as independent variables, as well as the pre- to post-treatment change in apparent diffusion coefficient (delta ADC). Using cautious criteria, CRE and MR imaging with DWI (reader 1/reader 2) have comparable high specificity (83% and 89%/95%, respectively), whereas MR imaging without DWI showed significantly lower specificity (63%/53%) than CRE. Using strict criteria, CRE and MR imaging with DWI both showed very high specificity (99% and 92%/95%, respectively), whereas MR imaging without DWI showed significantly lower specificity (89%/77%) than CRE. All sensitivities were not significantly different. Addition of MR imaging with DWI to CRE has statistically significant incremental value in identifying residual tumour (reader 1: estimate, 1.06; p = 0.001) (reader 2: estimate, 0.62; p = 0.02). Adding the delta ADC did not have significant incremental value in detecting residual tumour. DWI significantly increases the specificity of MR imaging in the detection of local residual tumour. Furthermore, MR imaging with DWI has significant incremental diagnostic value over CRE, whereas adding the delta ADC has no incremental diagnostic value. • If MR imaging is used for response evaluation, DWI should be incorporated • MR imaging with DWI has diagnostic value comparable/complementary to clinical response evaluation • Inter-reader agreement is moderate to fair for two experienced radiologist readers • Quantitative measurements of ADC early post-therapy have limited diagnostic value.

Identifiants

pubmed: 29943182
doi: 10.1007/s00330-018-5510-3
pii: 10.1007/s00330-018-5510-3
pmc: PMC6291430
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-318

Subventions

Organisme : Nuts-Ohra
ID : 1002-043

Références

Gynecol Oncol. 2000 Aug;78(2):187-93
pubmed: 10926801
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):442-8
pubmed: 11567819
Obstet Gynecol. 2002 May;99(5 Pt 1):855-67
pubmed: 11978302
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225
pubmed: 16034873
Cancer. 2008 Oct 15;113(8):2158-65
pubmed: 18780318
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):713-8
pubmed: 19427739
Gynecol Oncol. 2009 Sep;114(3):528-35
pubmed: 19560188
Radiology. 2009 Oct;253(1):116-25
pubmed: 19789256
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006377
pubmed: 20091593
Clin Oncol (R Coll Radiol). 2010 Sep;22(7):590-601
pubmed: 20594810
Radiother Oncol. 2010 Aug;96(2):153-60
pubmed: 20663578
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):609-14
pubmed: 21215531
Ann Surg Oncol. 2011 Aug;18(8):2224-31
pubmed: 21347783
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Ann Oncol. 2012 Oct;23 Suppl 7:vii27-32
pubmed: 22997451
Eur Radiol. 2013 Jul;23(7):2005-18
pubmed: 23455762
Acta Oncol. 2013 Oct;52(7):1510-9
pubmed: 23962242
Eur J Surg Oncol. 2013 Dec;39(12):1428-34
pubmed: 24183796
Radiology. 2014 Feb;270(2):454-63
pubmed: 24471390
J Magn Reson Imaging. 2015 Sep;42(3):572-94
pubmed: 25346470
Clin Breast Cancer. 2015 Oct;15(5):370-80
pubmed: 25891905
Eur J Surg Oncol. 2015 Aug;41(8):975-85
pubmed: 25922209
Eur Radiol. 2016 Sep;26(9):3272-9
pubmed: 26685853
Curr Oncol. 2016 Apr;23(2):109-18
pubmed: 27122975
Radiology. 2017 Aug;284(2):432-442
pubmed: 28301309

Auteurs

Maarten G Thomeer (MG)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. m.thomeer@erasmusmc.nl.
Department of Radiology, Erasmus Medical Center Rotterdam, P.O Box 2040, 3015, CE, Rotterdam, The Netherlands. m.thomeer@erasmusmc.nl.

Vincent Vandecaveye (V)

Department of Radiology, University Hospitals Leuven, Leuven, Belgium.

Loes Braun (L)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Frenchey Mayer (F)

Department of Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Martine Franckena-Schouten (M)

Department of Radiotherapy, Erasmus University Medical Center, Rotterdam, The Netherlands.

Peter de Boer (P)

Department of Radiotherapy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Jaap Stoker (J)

Department of Radiology and Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Erik Van Limbergen (E)

Department of Radiotherapy, University Hospitals Leuven, Leuven, Belgium.

Marrije Buist (M)

Department of Gynecology Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Ignace Vergote (I)

Department of Gynecology, University Hospitals Leuven, Leuven, Belgium.

Myriam Hunink (M)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Helena van Doorn (H)

Department of Radiology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH